Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout
Proteins and Peptides

Human Cathepsin V (CTSV), Active Protein

Product Sizes
50 ug
£957.00
RPU54959-50UG
100 ug
£1166.00
RPU54959-100UG
1 mg
£4824.00
RPU54959-1MG
About this Product
SKU:
RPU54959
Additional Names:
Cathepsin L2|CATL2|CTS-L2|CTS-V|CTSL2|CTSU
Application:
Detection/Quantitation, Tissue Culture
Buffer:
Freeze-dried powder|PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
CE/IVD:
RUO
Extra Details:
Human Cathepsin V (CTSV), Active Protein is a purified Prokaryotic Protein.
Formulation:
Freeze-dried powder
Immunogen:
Cathepsin V (CTSV)
Molecular Weight:
32kDa
Physical State:
freeze-dried
Purity:
>95%
Shipping Conditions:
Blue Ice
Storage Conditions:
-20[o]C Avoid freeze/thaw cycles.
Supplier:
Biomatik
Type:
Proteins, Peptides, Small Molecules & Other Biomolecules: Recombinant Proteins
Catalog Protein.JPG
Cathepsin V (CTSV) is a lysosomal cysteine proteinase which belongs to peptidase C1 family. It is expressed in normal human thymus, testis and corneal epithelium. Cathepsin V plays an important role in corneal physiology and mediates degradation of invariant chain in human thymus. Besides, Retinoblastoma Protein 1 (RB1) has been identified as an interactor of CTSV, thus a binding ELISA assay was conducted to detect the interaction of recombinant human CTSV and recombinant human RB1. Briefly, CTSV were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to RB1-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-CTSV pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50uL stop solution to the wells and read at 450nm immediately. The binding activity of CTSV and RB1 was shown in Figure 1, and this effect was in a dose dependent manner.
Figure 2. SDS-PAGE